News
FDMT
25.39
+6.10%
1.46
4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution
4D Molecular Therapeutics, Inc. Is a biotechnology company that develops genetic medicines using its Therapeutic Vector Evolution platform. The company's pipeline includes promising ophthalmology, pulmonology, and cardiology candidates. FDMT's platform allows for quickly creating custom viral vectors tailored to specific diseases. I believe FDMT stock is a strong buy driven by its innovative platform and a robust pipeline.
Seeking Alpha · 2d ago
Weekly Report: what happened at FDMT last week (0422-0426)?
Weekly Report · 2d ago
Weekly Report: what happened at FDMT last week (0415-0419)?
Weekly Report · 04/22 09:28
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
Cathie Wood's fund ARK Invest invests in companies she expects to be the leaders of disruptive innovation. The fund is down 15% this year. Wood is a fan of investing in the companies of tomorrow. Her fund invests in the cutting-edge technologies of the day.
Benzinga · 04/18 18:29
4D Molecular Therapeutics Price Target Raised to $40.00/Share From $35.00 by RBC Capital
Dow Jones · 04/15 17:23
4D Molecular Therapeutics Is Maintained at Outperform by RBC Capital
Dow Jones · 04/15 17:23
RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $40
Benzinga · 04/15 17:13
4D Molecular Therapeutics new overweight at Barclays on genetic medicine platform
Barclays has started 4D Molecular Therapeutics at overweight. The firm has a $45 price target for the stock. The company's lead asset, 4D-150, is a gene therapy candidate for macular degeneration. Barclays cites the validation of the company's AAV vector technology for delivering gene therapies.
Seeking Alpha · 04/15 16:22
Institutional owners may ignore 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) recent US$83m market cap decline as longer-term profits stay in the green
A total of 7 investors have a majority stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) with 52% of the company. Institutional investors own a large portion of the stock, but the company is not owned by all of them. 7 of the top 7 shareholders have a 50% stake in the company with 50% of its shares. The company is owned by institutions and hedge funds. 4D molecular therapeutics has a meaningful stake of US$48m in theCompany. We look at the ownership groups of 4d moleculartherapeutics and other companies.
Simply Wall St · 04/15 11:16
4D Molecular Therapeutics Price Target Announced at $45.00/Share by Barclays
Dow Jones · 04/15 11:16
4D Molecular Therapeutics Initiated at Overweight by Barclays
Dow Jones · 04/15 11:16
Barclays Initiates Coverage On 4D Molecular Therapeutics with Overweight Rating, Announces Price Target of $45
Benzinga · 04/15 11:06
RBC Capital Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)
TipRanks · 04/15 10:55
4D MOLECULAR THERAPEUTICS INC <FDMT.O>: BARCLAYS INITIATES COVERAGE WITH OVERWEIGHT RATING AND TARGET PRICE $45
Reuters · 04/15 10:31
Weekly Report: what happened at FDMT last week (0408-0412)?
Weekly Report · 04/15 09:26
4D MOLECULAR THERAPEUTICS INC <FDMT.O>: RBC RAISES TARGET PRICE TO $40 FROM $35
Reuters · 04/15 09:13
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Acadia Healthcare (ACHC) and Coherus Biosciences (CHRS)
TipRanks · 04/15 08:30
Weekly Report: what happened at FDMT last week (0401-0405)?
Weekly Report · 04/08 09:28
4D Molecular Therapeutics Price Target Cut to $63.00/Share From $70.00 by BMO Capital
Dow Jones · 04/01 16:28
4D Molecular Therapeutics Is Maintained at Outperform by BMO Capital
Dow Jones · 04/01 16:28
More
Webull provides a variety of real-time FDMT stock news. You can receive the latest news about 4D Molecular Therapeutics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About FDMT
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.